Kilatim (Timolol Maleate, Latanoprost)

Timolol maleate is a non‑selective beta‑adrenergic blocker. By inhibiting β‑receptors in the ciliary body, it reduces the production of aqueous humor, which lowers the pressure inside the eye.

The dosing regimen for Kilatim is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily, but the exact frequency and duration are individualized based on patient response.

Safety of Kilatim in pregnancy or lactation has not been fully established. Healthcare providers should weigh potential benefits against risks and consider alternative treatments if appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Kilatim combines a beta‑blocker and a prostaglandin analog, offering dual mechanisms—reduced aqueous humor production and increased outflow. This can provide greater pressure reduction than single‑agent drops, though individual response varies and tolerability must be considered.

Kilatim should be stored at room temperature, below 25 °C. Keep the bottle in its original packaging, protect it from direct sunlight and moisture, and discard any solution that appears discolored or contains particles.

Kilatim is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and place one drop into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks include severe allergic reactions, ocular inflammation, sudden vision loss, systemic bradycardia, and bronchospasm. Patients should seek immediate medical attention if they experience swelling, severe eye pain, rapid vision changes, or breathing difficulties.

Kilatim is contraindicated in patients with known hypersensitivity to timolol, latanoprost, or any component of the formulation, as well as those with severe sinus node dysfunction, uncontrolled asthma, or active ocular infections.